Valeant Pharmaceuticals Completes Sale Of Filler And Toxin Assets To Galderma

Valeant Pharmaceuticals Completes Sale Of Filler And Toxin Assets To Galderma 
LAVAL, Quebec, July 10, 2014 /CNW/ - Valeant Pharmaceuticals International, 
Inc. (NYSE: VRX and TSX: VRX) today announced it has completed the sale to 
Galderma of all rights to Restylane, Perlane, Emervel, Sculptra, and Dysport 
owned or held by Valeant for $1.4 billion in cash, pursuant to the previously 
announced agreement with Nestle S.A, which recently completed its acquisition 
of Galderma. 
"We are pleased to complete the divestiture of our products to a company that 
is firmly committed to the aesthetic dermatology market," said J. Michael 
Pearson, chairman and chief executive officer.  "Humberto Antunes, CEO of 
Galderma, has embraced our commercial team and I know he will continue our 
efforts to build strong relationships with the healthcare leaders in this 
industry." 
About Valeant Pharmaceuticals International, Inc. 
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational 
specialty pharmaceutical company that develops, manufactures and markets a 
broad range of pharmaceutical products primarily in the areas of dermatology, 
eye health, neurology and branded generics.  More information about Valeant 
Pharmaceuticals International, Inc. can be found at www.valeant.com. 
Contact Information: 
Laurie W. Little 949-461-6002  laurie.little@valeant.com 
Logo - http://photos.prnewswire.com/prnh/20101025/LA87217LOGO
 

SOURCE  Valeant Pharmaceuticals International, Inc. 
http://www.valeant.com 
http://photos.prnewswire.com/prnh/20101025/LA87217LOGO 
To view this news release in HTML formatting, please use the following URL: 
http://www.newswire.ca/en/releases/archive/July2014/10/c7349.html 
CO: Valeant Pharmaceuticals International, Inc.
ST: Quebec
NI: HEA MTC BTC MNA  
-0- Jul/10/2014 13:31 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.